GSK Advances Toward Functional Cure for Chronic Hepatitis B
After two successful Phase 3 studies, GSK's bepirovirsen demonstrates functional cure rates for chronic hepatitis B patients, potentially providing an alternative to lifelong antiviral regimens.
Key Developments
- GSK’s bepirovirsen met the main goal in two Phase 3 trials aimed at achieving a functional cure for chronic hepatitis B infection.
- The therapy is an antisense oligonucleotide that could serve as an alternative to current antiviral drugs requiring lifelong administration.
Implications
- This advancement addresses a critical unmet need for hepatitis B patients seeking a finite treatment.
- A functional cure could significantly reduce the long-term burden of chronic hepatitis B globally.
Outlook
- Pending regulatory review, bepirovirsen could usher in a new treatment paradigm for hepatitis B.
- Further real-world data will be essential to confirm durability and safety of the functional cure.
Source: MedCity News
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.